Hazard curvature makes within-host variability costly for survival.

Publication date: Jul 28, 2026

Tumors, pathogens, and immune responses are increasingly modeled as ecological and evolutionary systems inside hosts. Yet the clinically meaningful endpoint is usually not the trajectory of those internal populations but the fate of the host. In this article a framework is developed that links mechanistic within-host dynamics to outcomes through a hazard map. The framework gives rise to a curvature principle: If the instantaneous hazard is a convex function of a harmful host state, variability in that state is costly: That is, among trajectories with the same temporal mean, the path with least variance minimizes cumulative hazard, and any mean-preserving spread increases it. A local expansion shows that the penalty is set by hazard curvature and temporal variance. We extend the framework to proportional-hazards joint models, where the standard exponential link is convex by construction. This yields a curvature penalty, 1/2 γ.Var(z), such that for sinusoidal trajectories under a constant baseline hazard, an exact Bessel-function expression, I(γA), for cumulative-hazard inflation is described. Both quantities can be derived from fitted joint models and quantify when the variability in the trajectory is likely to matter. The same framework highlights an endpoint mismatch: Strategies that improve burden-based control metrics, such as time to threshold, can worsen survival by repeatedly visiting high-risk states. The theory is illustrated with competitive tumor dynamics, a pathogen-immune-damage model and an example using parameters from a published joint model of SARS-CoV-2 viral kinetics and mortality. Hazard curvature links within-host dynamics, time-to-event outcomes, and treatment design.

Open Access PDF

Concepts Keywords
Ecological Animals
Fate COVID-19
Models hazard
Tumors Host-Pathogen Interactions
Viral Humans
Models, Biological
Neoplasms
Proportional Hazards Models
SARS-CoV-2
survival
time-to-event analysis
within-host ecology

Semantics

Type Source Name
disease MESH Tumors
pathway REACTOME Translation
drug DRUGBANK Coenzyme M
disease MESH eco
disease MESH death
drug DRUGBANK Spinosad
disease MESH infectious disease
pathway REACTOME Infectious disease
disease MESH ect
disease MESH Severe acute respiratory syndrome
disease MESH PSA
disease MESH relapse
drug DRUGBANK Aspartame
drug DRUGBANK Carboplatin
drug DRUGBANK Trestolone
disease MESH ovarian cancer
disease MESH frailty
disease MESH prostate cancer
pathway KEGG Prostate cancer
disease MESH cap
disease MESH inflammation
disease MESH infection
disease MESH clinical progression
disease MESH breast cancer
pathway KEGG Breast cancer
disease MESH CRC
drug DRUGBANK Platinum
disease MESH COVID-19

Original Article

(Visited 3 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *